Johnson & Johnson Newsroom

Express News | Johnson & Johnson Medtech Announces Ce Mark Approval for Dual Energy Thermocool Smarttouch™ Sf Catheter

BreakingsJan 10 21:00

Johnson & Johnson MedTech Announces CE Mark Approval for Dual Energy THERMOCOOL SMARTTOUCH SF Catheter

PR NewswireJan 10 21:00

Goldman Sachs Adjusts Price Target on Johnson & Johnson to $158 From $159, Keeps Neutral Rating

MT NewswiresJan 10 18:48 · Ratings

Johnson & Johnson Pauses US Varipulse Procedures Amid Safety Review, Investigates Brain-Related Events

BenzingaJan 10 01:46

Novo, Eli Lilly to Dominate Global Pharma Sales in 2025: Report

Seeking AlphaJan 9 21:56

Wells Fargo Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $166

Futu NewsJan 9 21:33 · Ratings

Johnson & Johnson Gets FDA Priority Review of Nipocalimab in Generalized Myasthenia Gravis

WSJJan 9 21:27

Express News | J&J: Nipocalimab Granted U.S. FDA Priority Review for the Treatment of Generalized Myasthenia Gravis (Gmg)

BreakingsJan 9 21:02

J&J Pauses Sales of Atrial Fibrillation Device, Stock Down

Zacks Jan 9 21:00

Express News | Arkuda Therapeutics: J&J Exercised Option to Buy Co's Portfolio of Lysosomal Function Enhancers for Upfront Payment & Extra Milestone Payments

BreakingsJan 9 20:04

Arkuda Therapeutics Announces Option Exercise and Asset Purchase

PR NewswireJan 9 20:00

Johnson & Johnson's drug for treating Alzheimer's disease has received FDA fast track designation.

On January 9, Glonghui reported that Johnson & Johnson announced on Wednesday that its proposed drug posdinemab for the treatment of Alzheimer's disease has been granted Fast Track designation by the USA Food and Drug Administration (FDA). Johnson & Johnson is conducting a Phase 2b study on early Alzheimer's patients to investigate an internally developed tau-targeted monoclonal antibody. The company stated that posdinemab shows potential against disease-related phosphorylated tau proteins in the cerebrospinal fluid of Alzheimer's patients, and it has been shown to prevent the development and Diffusion of tau protein aggregation in nonclinical models of memory deprivation disease.

Gelonghui FinanceJan 9 12:35

Bernstein Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Cuts Target Price to $160

Futu NewsJan 9 07:31 · Ratings

San Francisco Police Cancel Time Off as Healthcare Execs Descend -- Barrons.com

Barron'sJan 9 06:29

Johnson & Johnson Temporarily Pulls New Treatment for Atrial Fibrillation to Probe Adverse Events

MT NewswiresJan 9 04:57

Johnson & Johnson Falls After Pausing Varipulse Cases

Seeking AlphaJan 9 02:31

8 Health Care Stocks Whale Activity In Today's Session

BenzingaJan 9 01:35

Express News | J&J - as U.S. External Evaluation Leveraged Unique Platform Configuration, There Is No Impact to Commercial Activity & Varipulse Cases Outside of U.s

BreakingsJan 9 01:25

Express News | J&J: On Jan 5, Johnson & Johnson Medtech Temporarily Paused U.S. External Evaluation and All U.S. Varipulse Cases

BreakingsJan 9 01:24

Express News | Johnson & Johnson Statement on Varipulse™ U.S. External Evaluation

BreakingsJan 9 01:24